Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review.

摘要: The development of inhibitors that neutralise the function factor VIII (FVIII) is currently not only most challenging complication associated with treatment haemophilia A but it also increases disease-related morbidity as bleeding episodes do respond to standard therapy. main short-term goal inhibitor patients control while long-term one permanently eradicate by immune tolerance induction, particularly in case high-titer antibodies. Due some vitro studies and clinical observations, investigators have suggested FVIII concentrates containing von Willebrand (VWF) may be less immunogenic than high-purity or recombinant products. It has been success rates for induction are higher when plasma-derived products used. available data from laboratory on role VWF eradication critically analysed this review. As a result, we found definitive evidence supporting product type incidence patients.